Skip to main content
Skip to main content

Substituted Heterocyclic Mercaptosulfonamide Metalloprotease Inhibitors

Tech ID:
Principal Investigator:
Dr. Qing-Xiang (Amy) Sang
Licensing Manager:

Dr. Sang's team developed a series of substituted heterocyclic mercaptosulfonamide compounds, precursors, and derivatives as well as methods for the preparation of and pharmaceutical compositions comprising these compounds. These compounds are designed to be potent selective inhibitors of matrix metalloproteinases (MMPs), including, for example, gelatinases, collagenases, matrilysins, metalloelastase, stromelysin, and membrane-type 1 matrix metalloproteinase. These inhibitors may be used for the control of physiological and pathological processes and disease conditions in which MMPs are believed to play significant functions.